A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. - Concepedia

Concepedia

Publication | Closed Access

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

434

Citations

19

References

1992

Year

M. Fukuoka, H Niitani, Atsushi Suzuki, Masakichi Motomiya, Kazuo Hasegawa, Yutaka Nishiwaki, T Kuriyama, Y Ariyoshi, Shunichi Negoro, N Masuda

Journal of Clinical Oncology

Abstract

CPT-11 is a very active agent for NSCLC with acceptable toxicities. Further trials in combination with other agents for this disease are warranted.

References

	Year	Citations

Page 1